Novavax’s Vaccine Switched Manufacturing Facilities Multiple Times Prior To EUA
Executive Summary
One switch raised questions, but by the time the COVID-19 vaccine reached commercial scale, the changes were considered minor.
You may also be interested in...
Depression And COVID-19 Vaccines: US FDA Notes ‘Imbalance’ In Novavax Trial For Adolescents
But agency assessors also said there did not appear to be a biological reason for the vaccine to cause depression when granting the emergency use authorization for use of the Novavax vaccine in 12- to 17-year-olds.
ACIP Nod For Novavax’s COVID Vaccine Comes With Criticism On Lack Of Expiration Date Packaging
Providers will have to look up the expiration date for vials of the protein-based vaccine on a website because it is not printed on the carton or packaging; omission sparks ACIP members’ frustrations with FDA and manufacturers about inadequate packaging for some other recently authorized vaccines.
Novavax EUA Justified By US FDA With Claims Of COVID Vaccine Supply Constraints
The agency also includes a myocarditis warning in the fact sheet for the first protein-based COVID-19 vaccine to reach the US market.